ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 2018-002WIRB]


The purpose of this study is to show non-inferiority of the primary endpoint of all death or all MI (modified ARC) from 3 to 12 months following XIENCE implantation in HBR subjects with HBR treated with 3-month DAPT compared to a historical control after propensity score adjustment.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-7512